Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) discovered a new and potentially revolutionary way to treat glioblastoma (GBM), the most aggressive type of brain cancer with no curative treatment options. An innovative study – led by Paul B. Fisher, MPh, Ph.D., FNAI, and Swadesh K. Das, Ph.D., and recently published in the Journal for ImmunoTherapy of Cancer – created a novel molecule that demonstrated the capability to introduce a combination of treatment outcomes – direct toxicity and immunotoxicity – to kill the tumor while exploiting immunotherapy to potentially prevent the recurrence of GBM via a “Fusion Superkine” (FSK), containing dual acting therapeutic cytokines in a single molecule.

Opioids like fentanyl, morphine and oxycodone are the drugs most linked to overdoses in the U.S. Typical screening methods for drug usage involve collection of blood, saliva or urine samples. Now, in ACS’ Analytical Chemistry, researchers demonstrate a pen-like tool that can quickly and non-invasively collect molecules from the skin’s surface to be screened for opioids with mass spectrometry.

BUFFALO, NY – June 24, 2025 – A new precision oncology paper was published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.”

On April 29th, the Vaccine Innovation Center (Director Chung Hee-Jin) of Korea University's College of Medicine successfully held a special seminar with Professor Pierre Van Damme, a world-renowned vaccine expert, at the Yoon Joo-Hong lecture room, 4th floor main building. 61 researchers joined this seminar to have in-depth discussions on the latest research trends and strategies in vaccine development and clinical trials.